An estimated 3 out of 10 people using cannabis have a cannabis-related disorder, which suggests many are at risk for any adverse health effects.

Comparison of pre- and postintervention measures demonstrated that AI chatbots can effectively improve education and attitudes of patients with breast cancer.

The R2-MTX and POR/ROM regimens achieved higher response rates than R-MTX but showed no statistical advantage in overall survival.

Positive associations seen for celiac disease, SLE, T1D with pancreatic, esophageal, colon, liver, and hepatobiliary cancers.

UTUC has distinct molecular alterations, so bladder recurrences and treatment efficacy might differ from primary bladder carcinoma.

Researchers sought to determine whether combination talquetamab and teclistamab would be a viable treatment option for patients with RRMM and EMD.

43.2 percent missed opportunity rate reported for germline genetic testing, risk-reducing surgery in those with affected first-degree relative.

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

Researchers explored immunoglobulin replacement therapy patterns and the effect of serious infection in a real-world cohort of patients with CLL.

Researchers investigated the relationship between antiplatelet medication and the risk for liver fibrosis, PVT, and hepatocellular carcinoma.

Models estimated patient’s lifetime risk of dying from nonmetastatic prostate cancer rather than other causes.